CDC Cannabis Health Data Collection — Federal Surveys and Public Health Research

Executive Summary

The Centers for Disease Control and Prevention (CDC) proposed in August 2026 to add medical cannabis usage questions to the National Health Interview Survey (NHIS), marking the first systematic federal effort to collect population-level data on medical marijuana consumption patterns. The proposal, submitted for public comment through the Office of Management and Budget (OMB), would require respondents to disclose whether they use cannabis for medical purposes, the conditions they treat, frequency of use, and method of consumption. This represents a significant policy shift for a federal agency operating under the constraints of the Controlled Substances Act, where cannabis remains a Schedule I substance despite widespread state-level legalization. The CDC's move comes as 38 states have legalized medical cannabis programs, creating a data vacuum that has hampered public health research, clinical guidance development, and evidence-based policymaking for nearly three decades.

The proposed data collection would affect approximately 35,000 households surveyed annually through NHIS, the nation's principal source of health statistics. Public health researchers have long criticized the absence of standardized federal cannabis health data, noting that current surveillance relies on fragmented state registries, voluntary reporting systems, and emergency department visit tracking through the Drug Abuse Warning Network. The CDC initiative faces potential opposition from cannabis reform advocates concerned about patient privacy and federal data sharing with law enforcement agencies, while simultaneously drawing scrutiny from prohibitionist organizations that view federal acknowledgment of medical use as legitimizing a Schedule I substance. The comment period closed September 26, 2026, with implementation potentially beginning in the 2027 survey cycle pending OMB approval.

Why This Matters

Systematic federal health data collection on cannabis use would fill a critical evidence gap affecting 6.2 million registered medical cannabis patients across state programs, thousands of physicians making treatment recommendations, and policymakers crafting regulations in a data-poor environment. The absence of population-level surveillance has created what the National Academies of Sciences, Engineering, and Medicine characterized in their 2017 cannabis health effects review as "a lack of definitive evidence" for most therapeutic applications, despite decades of state-sanctioned medical use.

The financial stakes are substantial. The medical cannabis market generated $8.4 billion in sales during 2025 according to industry analytics firms, with multi-state operators (MSOs) and single-state licensees serving patients who currently navigate treatment decisions without FDA-approved labeling, standardized dosing guidelines, or longitudinal outcome data. Physicians in medical cannabis states operate under recommendation systems rather than prescription authority, partly due to the absence of clinical trial data and post-market surveillance that would normally inform prescribing practices.

For patients, the data gap has real consequences. Insurance companies categorically exclude cannabis from coverage, citing the lack of FDA approval and clinical evidence—a circular problem when federal prohibition under 21 U.S.C. § 812 has blocked the large-scale clinical trials that would generate such evidence. Out-of-pocket costs for medical cannabis patients average $300-600 monthly according to patient surveys, with no ability to use Health Savings Accounts or Flexible Spending Accounts for purchases of a Schedule I substance.

The CDC proposal also matters for harm reduction. Emergency department visits involving cannabis increased 37% between 2016 and 2023 according to the Drug Abuse Warning Network, but without systematic data on usage patterns, denominator populations, or risk factors, public health officials cannot calculate accurate adverse event rates or identify high-risk consumption behaviors. State poison control centers report rising calls related to edible cannabis products and high-potency concentrates, yet no federal surveillance system tracks these incidents comprehensively.

Background and History

The federal government's relationship with cannabis health data collection has been characterized by prohibition-era surveillance focused on illicit use rather than therapeutic applications, creating a 30-year gap since California launched the modern medical cannabis era in 1996.

The Controlled Substances Act Era (1970-1996)

When Congress passed the Controlled Substances Act in 1970, establishing the drug scheduling system under 21 U.S.C. § 812, cannabis was placed in Schedule I based on findings of "no currently accepted medical use" and "high potential for abuse." This classification shaped all subsequent federal data collection efforts. The National Institute on Drug Abuse (NIDA) became the sole federal agency authorized to cultivate cannabis for research, focusing its mission on documenting harms rather than therapeutic potential. The CDC's existing surveillance systems—including the Behavioral Risk Factor Surveillance System (BRFSS) and Youth Risk Behavior Survey (YRBS)—asked about cannabis use exclusively in the context of substance abuse and risk behaviors.

The National Household Survey on Drug Abuse, launched in 1971 and later renamed the National Survey on Drug Use and Health (NSDUH), established the template for federal cannabis data collection: questions about lifetime use, past-year use, age of initiation, and frequency, all framed within a substance abuse prevention framework. Medical use was not a category; all consumption was classified as illicit drug use.

State Medical Cannabis Programs Emerge (1996-2010)

California's Proposition 215, passed by voters in November 1996, created the first state-legal medical cannabis program in direct conflict with federal law. The Compassionate Use Act allowed patients with a physician's recommendation to possess and cultivate cannabis for conditions including cancer, AIDS, chronic pain, and other illnesses. The federal response was hostile: the Drug Enforcement Administration (DEA) threatened to revoke prescribing licenses of physicians who recommended cannabis, leading to the Conant v. Walters litigation that ultimately protected physician speech rights.

Critically, no federal agency moved to study the health outcomes of California's medical cannabis patients. The CDC did not add questions to NHIS. NIDA did not launch observational cohort studies. The FDA maintained that cannabis had no accepted medical use, creating a circular logic: state programs could not generate the evidence needed for federal acceptance because federal agencies refused to collect or recognize such evidence.

By 2010, 15 states had enacted medical cannabis laws, each creating its own patient registry with different qualifying conditions, possession limits, and data collection practices. Colorado required patients to register with the state health department; California operated a voluntary ID card system with low enrollment; Michigan's registry was confidential under state law. This fragmentation made cross-state analysis impossible and population-level health surveillance non-existent.

The Obama Administration and Cole Memo Era (2010-2017)

The 2009 Ogden Memo and 2013 Cole Memo established federal enforcement priorities that deprioritized prosecution of state-compliant medical cannabis operations, but neither directive addressed health data collection. The Department of Health and Human Services (HHS) continued to classify cannabis as Schedule I with no medical value, while the CDC's surveillance systems continued to categorize all use as illicit drug consumption.

A significant development occurred in 2014 when Congress passed the Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), prohibiting the Department of Justice from using funds to interfere with state medical cannabis programs. This appropriations rider, renewed annually, created legal space for state programs to operate but included no provisions for federal health research or data collection.

The National Academies of Sciences, Engineering, and Medicine released a comprehensive review in January 2017 titled "The Health Effects of Cannabis and Cannabinoids," finding substantial evidence for cannabis effectiveness in treating chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity—but noting that most evidence came from international studies and small U.S. trials, not from the millions of patients in state medical programs.

State Legalization Accelerates (2017-2024)

By 2020, 33 states had legalized medical cannabis, and 11 had legalized adult-use programs that included medical patients. The COVID-19 pandemic highlighted the data gap: when most states classified cannabis dispensaries as essential businesses in March 2020, public health officials had no systematic data on how many patients relied on cannabis for symptom management, what conditions they treated, or what would happen if access was disrupted.

The CDC's COVID-19 response included extensive health surveys and data collection efforts, but none asked about medical cannabis use despite emerging research on cannabis and respiratory health, immune function, and potential drug interactions with COVID-19 treatments. The agency's Morbidity and Mortality Weekly Report (MMWR) published articles on vaping-associated lung injury (EVALI) in 2019-2020, which initially implicated cannabis vaping before identifying vitamin E acetate in illicit THC cartridges as the primary cause—an investigation hampered by the lack of baseline data on vaping prevalence and product types among medical users.

Federal Rescheduling Discussions (2024-2026)

In August 2024, the DEA published a Notice of Proposed Rulemaking (NPRM) to reschedule cannabis from Schedule I to Schedule III under 21 U.S.C. § 811, based on an HHS recommendation concluding that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The NPRM cited FDA analysis of state medical cannabis programs, international medical use, and clinical literature—but acknowledged the absence of systematic U.S. population health data.

The rescheduling proposal triggered over 43,000 public comments and remains pending as of August 2026, with an Administrative Law Judge (ALJ) hearing scheduled for late 2026. The HHS recommendation specifically noted that better post-market surveillance data would strengthen the evidence base for medical use—creating policy pressure for agencies like the CDC to develop data collection mechanisms.

Against this backdrop, the CDC's August 2026 proposal to add medical cannabis questions to NHIS represents the first concrete federal effort to systematically collect health data on medical use, nearly 30 years after California voters approved Proposition 215.

Key Players

Centers for Disease Control and Prevention (CDC)

The CDC, operating under the Department of Health and Human Services, manages the National Health Interview Survey and multiple surveillance systems that have historically excluded medical cannabis use as a data point. The agency's National Center for Health Statistics (NCHS) conducts NHIS as an annual cross-sectional household survey covering approximately 35,000 households. The CDC's proposal to add medical cannabis questions represents a significant methodological and policy shift, requiring the agency to acknowledge therapeutic use of a Schedule I substance while maintaining its public health mission. The agency has faced criticism from researchers for its slow response to the cannabis policy landscape; a 2023 Government Accountability Office (GAO) report noted that CDC surveillance systems had not adapted to capture medical and adult-use legalization trends despite their public health implications.

Office of Management and Budget (OMB)

OMB's Office of Information and Regulatory Affairs (OIRA) must approve all federal surveys under the Paperwork Reduction Act before implementation. The agency reviews survey questions for burden on respondents, necessity of data collection, and consistency with federal policy. OMB's approval process includes a 60-day public comment period, which the CDC initiated in August 2026. OIRA has historically been cautious about cannabis-related data collection that might appear to legitimize medical use of a Schedule I substance, creating potential tension between public health data needs and drug control policy.

Drug Enforcement Administration (DEA)

The DEA maintains cannabis as a Schedule I controlled substance under 21 U.S.C. § 812, defining it as having no accepted medical use. The agency's pending rescheduling decision will directly impact the CDC's data collection: if cannabis moves to Schedule III, federal acknowledgment of medical use becomes official policy, removing potential legal obstacles to health surveillance. The DEA has historically opposed state medical cannabis programs and maintains that federal law preempts state legalization under the Supremacy Clause, though the Rohrabacher-Blumenauer Amendment limits enforcement. The agency does not conduct health surveillance but shares data with CDC on drug-related emergency department visits and deaths through the National Forensic Laboratory Information System.

Food and Drug Administration (FDA)

The FDA has approved four cannabis-derived or synthetic cannabinoid medications: Epidiolex (cannabidiol) for seizure disorders, and Marinol, Syndros, and Cesamet (synthetic THC analogs) for chemotherapy-induced nausea and AIDS wasting syndrome. The agency maintains that "marijuana" as a whole plant has not been approved as safe and effective for any indication, creating a distinction between FDA-regulated cannabinoid drugs and state medical cannabis programs. The FDA's drug approval process requires clinical trials and post-market surveillance—systems that do not exist for state medical cannabis. The agency has stated that better real-world evidence from state programs could inform future regulatory decisions, making CDC data collection potentially valuable for FDA policy development.

National Institute on Drug Abuse (NIDA)

NIDA, part of the National Institutes of Health, holds a federal monopoly on cannabis cultivation for research under a contract with the University of Mississippi. The agency's mission focuses on substance abuse and addiction, and it has been criticized by medical cannabis researchers for prioritizing studies of harms over therapeutic potential. NIDA funding has supported some observational research on medical cannabis patients, but the agency does not conduct population-level surveillance. The institute's director has publicly stated that more data on medical use patterns would help identify both therapeutic applications and potential risks, suggesting support for CDC data collection efforts.

State Health Departments

The 38 states with medical cannabis programs operate independent patient registries with varying data collection practices. New York requires detailed quarterly reporting on patient conditions and product purchases; California's voluntary ID card system captures minimal data; Oklahoma's registry includes over 400,000 patients but does not track conditions or outcomes. State health departments have called for federal coordination and standardized metrics, as current fragmentation prevents cross-state analysis and national trend identification. Some states have expressed concern that federal data collection could create privacy risks if CDC shares information with law enforcement agencies, despite federal privacy protections for health survey data.

Medical Cannabis Industry

Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs serve medical patients across multiple jurisdictions but lack access to the population health data that would inform product development, dosing guidance, and patient education. The industry has generally supported federal research and data collection as a path toward legitimacy and potential FDA approval pathways, though some operators worry that adverse event data could fuel prohibitionist arguments. Industry trade groups including the National Cannabis Industry Association have advocated for federal research funding and data infrastructure.

Legal and Regulatory Framework

The CDC's proposed data collection operates within a complex legal framework where federal prohibition under the Controlled Substances Act conflicts with state medical cannabis laws, creating unique challenges for health surveillance.

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Section 812 places cannabis in Schedule I, defined as substances with "no currently accepted medical use in treatment in the United States" and "a lack of accepted safety for use under medical supervision." This classification creates a legal paradox: the CDC would be collecting data on medical use of a substance that federal law defines as having no medical use.

The Paperwork Reduction Act, 44 U.S.C. § 3501 et seq., requires OMB approval for federal surveys and establishes standards for data collection including minimizing burden on respondents and ensuring information quality. The Act requires agencies to justify the necessity of data collection and demonstrate that the information cannot be obtained from existing sources. The CDC's NHIS operates under a continuing OMB approval with periodic reviews for question modifications.

Privacy protections for health survey data come from multiple sources. The Public Health Service Act, 42 U.S.C. § 242m(d), prohibits the use of NHIS data for law enforcement purposes and makes individual responses confidential. The Confidential Information Protection and Statistical Efficiency Act (CIPSEA), 44 U.S.C. § 3501 note, provides additional protections for statistical data collected by federal agencies. These protections mean that even though cannabis possession remains a federal crime under 21 U.S.C. § 844, NHIS responses about medical cannabis use cannot be shared with the DEA or used for prosecution.

However, state-level privacy protections vary significantly. The Health Insurance Portability and Accountability Act (HIPAA) does not protect medical cannabis recommendations because physicians cannot "prescribe" a Schedule I substance; they provide recommendations or certifications outside the traditional prescription system. Some states have enacted specific privacy protections for medical cannabis registry data, while others allow law enforcement access under certain circumstances.

The Rohrabacher-Blumenauer Amendment, renewed annually in appropriations bills, prohibits the Department of Justice from using funds to prevent states from "implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana." This rider protects state programs from federal interference but does not affirmatively authorize medical use or require federal data collection.

The pending DEA rescheduling proposal under 21 U.S.C. § 811 would move cannabis to Schedule III, which includes substances with "currently accepted medical use in treatment in the United States." This rescheduling would resolve the legal contradiction between federal data collection on medical use and Schedule I status, though the proposal remains under review as of August 2026.

State-by-State Medical Cannabis Landscape

The 38 states with medical cannabis programs operate under widely varying regulatory frameworks, creating a fragmented landscape that federal data collection would help standardize and analyze.

California

California launched the modern medical cannabis era with Proposition 215 in 1996, establishing a physician recommendation system with broad qualifying conditions including "any other illness for which marijuana provides relief." The state operates a voluntary Medical Marijuana Identification Card program with low enrollment; most patients rely on physician recommendations without state registration. Possession limits are eight ounces of flower and six mature plants, though local jurisdictions can set higher limits. California's dual medical and adult-use market (legalized in 2016) has created challenges for medical program data collection as many patients purchase from adult-use retailers without medical registration. The state does not maintain comprehensive patient registry data, making population-level health surveillance impossible without federal survey efforts.

Colorado

Colorado legalized medical cannabis in 2000 and requires patient registration with the state health department. As of 2026, approximately 78,000 patients are registered for conditions including cancer, glaucoma, HIV/AIDS, cachexia, persistent muscle spasms, seizures, severe pain, and severe nausea. Possession limits are two ounces of flower and six plants (three mature). The state health department publishes annual reports with demographic data and qualifying condition breakdowns, but does not track health outcomes, product types, or adverse events systematically. Colorado's adult-use legalization in 2012 reduced medical patient enrollment as recreational access eliminated the need for medical registration for many users.

Florida

Florida's medical cannabis program, established by constitutional amendment in 2016 and expanded by legislation in 2017, has grown to over 800,000 registered patients as of 2026, making it one of the nation's largest programs. Qualifying conditions include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, and terminal conditions. The state requires physician certification and patient registration through the Office of Medical Marijuana Use. Possession limits are a 70-day supply determined by the physician, with no home cultivation allowed. Florida's registry includes data on patient demographics and certifying physicians but does not track product purchases, health outcomes, or adverse events in a publicly accessible format.

Illinois

Illinois established a medical cannabis pilot program in 2013, made it permanent in 2019, and legalized adult use in 2020. The medical program includes over 40 qualifying conditions and requires patient registration with the Department of Public Health. As of 2026, approximately 140,000 patients are registered. Medical patients receive advantages over adult-use consumers including higher possession limits (2.5 ounces per 14 days versus one ounce for adult use), lower taxes, and access to higher-potency products. The state publishes quarterly reports with patient counts by condition but does not conduct longitudinal health outcome studies.

New York

New York's medical cannabis program, launched in 2016 and significantly expanded in 2021, requires patient certification for qualifying conditions including cancer, HIV/AIDS, ALS, Parkinson's disease, multiple sclerosis, spinal cord injury, epilepsy, inflammatory bowel disease, neuropathy, Huntington's disease, PTSD, chronic pain, and any condition causing cachexia or wasting syndrome. The state initially prohibited smokable flower, allowing only oils, tinctures, and vaporization products, but lifted this restriction in 2021. New York's Office of Cannabis Management maintains a patient registry and requires dispensaries to report all sales, creating one of the most comprehensive state-level datasets. However, this data is not publicly accessible for research purposes, and the state does not publish detailed health outcome analyses.

Ohio

Ohio's Medical Marijuana Control Program, established in 2016 with sales beginning in 2019, requires patient registration for 26 qualifying conditions including cancer, chronic pain, epilepsy, fibromyalgia, glaucoma, HIV/AIDS, inflammatory bowel disease, multiple sclerosis, Parkinson's disease, PTSD, sickle cell anemia, spinal cord injury, Tourette syndrome, traumatic brain injury, and ulcerative colitis. As of 2026, approximately 230,000 patients are registered. The state's Board of Pharmacy tracks all transactions through a seed-to-sale system and publishes quarterly reports with patient demographics and product sales data. Ohio prohibits home cultivation and smoking of flower (vaporization is permitted), making it one of the more restrictive medical programs. The state has not conducted systematic health outcome studies despite having comprehensive transaction data.

Pennsylvania

Pennsylvania's medical marijuana program, launched in 2018, has grown to over 450,000 registered patients as of 2026. Qualifying conditions include 23 serious medical conditions such as cancer, epilepsy, glaucoma, HIV/AIDS, Parkinson's disease, multiple sclerosis, inflammatory bowel disease, neuropathies, PTSD, autism, and chronic pain. The state Department of Health maintains a patient and caregiver registry and requires dispensaries to report all sales. Pennsylvania prohibits smoking of flower products but allows vaporization, tinctures, oils, pills, topicals, and concentrates. The state publishes annual reports with patient counts and demographics but does not analyze health outcomes or adverse events systematically.

Market and Business Implications

Federal health data collection would provide the medical cannabis industry with population-level evidence that could inform product development, support insurance coverage advocacy, and potentially create pathways to FDA approval for specific formulations.

The medical cannabis market generated $8.4 billion in sales during 2025, representing approximately 28% of total legal cannabis sales as adult-use markets have expanded. Multi-state operators have increasingly focused on adult-use revenue due to higher margins and fewer regulatory restrictions, but medical programs remain critical for patient populations that require higher potency products, specific cannabinoid ratios, or tax advantages. Systematic health data could help MSOs identify underserved patient populations, optimize product formulations for specific conditions, and develop evidence-based dosing guidance that currently does not exist.

The absence of health outcomes data has created significant barriers to medical legitimacy. Insurance companies categorically exclude cannabis from coverage, citing lack of FDA approval and clinical evidence. The Internal Revenue Service applies 26 U.S.C. § 280E to cannabis businesses, disallowing deductions for business expenses related to trafficking in Schedule I substances, resulting in effective tax rates of 70% or higher. Rescheduling to Schedule III would eliminate 280E liability, but insurance coverage would still require clinical evidence of safety and efficacy—evidence that CDC population health data could help generate.

For investors, federal health data collection signals potential movement toward medical legitimacy and eventual FDA approval pathways. Pharmaceutical companies have largely avoided the cannabis sector due to federal prohibition and lack of intellectual property protection for plant-derived products. However, if CDC data identifies specific conditions where cannabis shows strong effectiveness and safety profiles, pharmaceutical investment could accelerate for synthetic or semi-synthetic cannabinoid drug development. This could create both opportunities and competitive threats for existing cannabis operators.

Wholesale pricing and cultivation decisions could also be informed by health data. Current medical cannabis production is driven by consumer preferences and budtender recommendations rather than clinical evidence. If CDC data shows that specific cannabinoid profiles are most effective for particular conditions, cultivators could optimize genetics and production for medical efficacy rather than THC potency alone. This could drive demand for strains high in CBD, CBG, or specific terpenes like myrcene, limonene, or linalool if health data supports their therapeutic value.

The data could also impact market structure. If federal surveillance identifies safety concerns with specific product types—such as high-potency concentrates or certain edible formulations—state regulators could impose restrictions that would affect product mix and revenue streams. Conversely, if data shows strong safety profiles for specific delivery methods like sublingual tinctures or transdermal patches, these categories could see increased market share.

What Experts Say

Public health researchers, physicians, and policy analysts have generally welcomed the CDC proposal while raising concerns about privacy protections, question design, and the potential for data to be misused by prohibitionist advocates.

Dr. Kevin Sabet, president of Smart Approaches to Marijuana, an organization opposing legalization, has argued that federal data collection should focus on adverse events and risks rather than therapeutic benefits. According to public statements, Sabet's organization believes that systematic surveillance will document harms including cannabis use disorder, impaired driving, and mental health effects, strengthening the case for stricter regulation.

The Drug Policy Alliance, a reform advocacy organization, has expressed support for health data collection while emphasizing the need for robust privacy protections. According to the organization's policy positions, federal surveys must include clear assurances that responses cannot be used for law enforcement purposes and that data will not be shared with immigration authorities or used to deny federal benefits.

Medical cannabis physicians have noted that the absence of population health data has made evidence-based practice nearly impossible. State medical boards in several jurisdictions have disciplined physicians for recommending cannabis, citing lack of evidence for therapeutic use—a circular problem when federal prohibition has blocked the research that would generate such evidence. Physician organizations have called for the CDC to include questions about dosing, product types, cannabinoid ratios, and patient-reported outcomes to maximize the clinical utility of collected data.

The American Public Health Association has supported federal cannabis health surveillance as part of a broader harm reduction approach. According to the organization's policy statements, public health agencies should treat cannabis similarly to alcohol and tobacco—legal substances that require ongoing surveillance to identify health risks, inform prevention efforts, and guide clinical practice.

State health officials have expressed mixed reactions. Some welcome federal coordination and standardized metrics that would enable cross-state comparisons. Others worry that federal data collection could undermine state registry systems if patients fear federal surveillance, potentially reducing enrollment in state programs that provide legal protections and access to regulated products.

What's Next

The CDC's medical cannabis data collection proposal faces several decision points and implementation challenges over the next 12-18 months that will determine whether systematic federal health surveillance becomes reality.

The immediate timeline centers on OMB approval. The 60-day public comment period that began in August 2026 closed on September 26, 2026. OIRA typically takes 60-90 days to review comments and issue a decision, suggesting a potential approval or denial by December 2026. If approved, the CDC would need to finalize question wording, train survey interviewers, and update data collection systems before implementation in the 2027 NHIS cycle, which begins in January.

The DEA's pending rescheduling decision represents a critical variable. If cannabis moves to Schedule III, federal acknowledgment of medical use becomes official policy, removing potential legal and political obstacles to CDC data collection. If the DEA maintains Schedule I status following the ALJ hearing, the CDC would be collecting data on medical use of a substance that federal law defines as having no medical use—a legally awkward but not impossible position given existing privacy protections for survey data.

Question design will be crucial. The CDC has not publicly released the specific survey questions proposed for NHIS, but public health researchers have identified key data points that should be included: qualifying conditions, product types (flower, concentrates, edibles, tinctures), consumption methods (smoking, vaporizing, oral, topical), frequency of use, dosing amounts, cannabinoid ratios (THC, CBD, other cannabinoids), concurrent medication use, perceived effectiveness, and adverse events. The more detailed the questions, the more useful the data for clinical and policy purposes—but also the greater the respondent burden and potential privacy concerns.

State coordination will be essential. If federal data collection proceeds without coordination with state registry systems, the result could be duplicative burden on patients and incompatible datasets. Some public health researchers have called for the CDC to work with state health departments to harmonize data collection, potentially integrating NHIS questions with state registry reporting to create a comprehensive national surveillance system.

Privacy safeguards will face ongoing scrutiny. Even with statutory protections under 42 U.S.C. § 242m(d) and CIPSEA, patient advocates may remain skeptical about federal data collection on an activity that remains a federal crime. The CDC will need to clearly communicate privacy protections and demonstrate that survey responses cannot be used for law enforcement purposes.

Long-term, if the CDC successfully implements medical cannabis questions on NHIS, other federal surveys may follow. The Behavioral Risk Factor Surveillance System, National Survey on Drug Use and Health, and other CDC surveillance systems could add similar questions, creating a comprehensive picture of medical cannabis use patterns across the U.S. population. This data infrastructure could eventually support the kind of post-market surveillance that exists for FDA-approved medications, potentially creating a pathway for cannabis products to achieve medical legitimacy even without traditional clinical trials.

Further Reading

• CDC National Health Interview Survey: https://www.cdc.gov/nchs/nhis/index.htm
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (August 2024): Federal Register Docket DEA-2024
• National Academies of Sciences, Engineering, and Medicine: "The Health Effects of Cannabis and Cannabinoids" (2017): https://www.nap.edu/catalog/24625
• HHS Recommendation to Reschedule Cannabis (August 2023): Available through FOIA requests
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Public Health Service Act confidentiality provisions, 42 U.S.C. § 242m(d): https://www.govinfo.gov/content/pkg/USCODE-2021-title42/pdf/USCODE-2021-title42-chap6A-subchapII-partA-sec242m.pdf
• State medical cannabis program data: Individual state health department websites and annual reports
• FDA guidance on cannabis and cannabis-derived compounds: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• NIDA research on medical cannabis: https://nida.nih.gov/research-topics/marijuana
• Government Accountability Office report on federal cannabis research barriers (2023): GAO-23-105